Recent Study: Product Profiles: Asthma - Key companies act to maintain dominance

July 19, 2012 - PRLog -- Asthma is an established and growing market dominated by key brands. However, competition is growing and generic threats are increasing, such that the market will become more fragmented. A number of pipeline products, notably once-daily ICS/LABA combinations, are expected to address unmet needs and have high clinical and commercial potential.

Report Scope

* Access Datamonitor's independent clinical and commercial assessment of marketed brands and key pipeline agents for asthma.
* Understand what it takes to differentiate a product in asthma treatment and how the pipeline threatens current market leaders.
* Assess how pipeline products compare to each other and how they will compete with established therapies.
* Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/434368_product_profiles_asthma_key_companies_act_to.aspx
------------------------------------------------------------

Report Highlights

Advair (GlaxoSmithKline) was the first ICS/LABA combination to launch but is expected to come under threat from generics and increasing competition, but with Phase III trials complete, its follow-on Relovair is on track to become the first once-daily ICS/LABA, which, if achieved, would ensure that the company maintains its market dominance.

Several biologics have advanced in the pipeline. Genentech's lebrikizumab is currently in large Phase III trials looking at exacerbations and AstraZeneca's tralokinumab and benralizumab are both in Phase II. Biologics could address unmet needs for subsets of uncontrolled patients, but key opinion leaders maintain skepticism over their viability.

Despite patent expiries for key ICS/LABA combinations, generics have not yet entered any of the seven major markets. Datamonitor believes that in the next couple of years they will launch as branded generics. Lower price discounts together with patients' hesitation to switch devices will help the brands resist generic erosion

Reasons to Get this Report

* How do marketed treatments of asthma compare to one another and where will pipeline agents fit in?
* How is GlaxoSmithKline protecting its market position in the face of increasing competition and looming generic entry?
* How can companies position their products at launch in order to compete in this well established market?
* How is asthma treatment expected to change as novel therapies move through the pipeline?

Partial Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Strategic scoping and focus
* Datamonitor key findings
* Related reports

MARKET DEFINITION AND OVERVIEW

* Market definition
* Product overview

MARKETED PRODUCT PROFILES

* Advair (fluticasone/salmeterol; GlaxoSmithKline)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Singulair (montelukast; Merck & Co.)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Symbicort (budesonide/formoterol; AstraZeneca)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Dulera (mometasone/formoterol; Merck & Co.)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Xolair (omalizumab; Genentech)

* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Other marketed drugs for asthma

* Flovent (fluticasone propionate; GlaxoSmithKline)
* Pulmicort (budesonide; AstraZeneca)
* Asmanex (mometasone; Merck & Co.)

PIPELINE PRODUCT PROFILES

* Flutiform (fluticasone/formoterol; SkyePharma)

* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline)

* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Lebrikizumab (MILR1444A; Genentech)

* Drug profile
* Development overview
* SWOT analysis
* Clinical and commercial assessment

* Masitinib (AB-1010; AB Science)

* Drug profile
* Development overview
* SWOT analysis
* Clinical and commercial assessment

* QMF149 (mometasone/indacaterol; Novartis)

* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial assessment

* Other pipeline drugs for asthma

* Andolast (CR2039; Rottapharm Madaus)
* Benralizumab (MEDI-563; Kyowa Hakko Kirin/AstraZeneca)
* CYT003-QbG10 (Cytos Biotechnology)
* KB003 (anti-GM-CSF MAb; KaloBios)
* Tralokinumab (CAT-354; AstraZeneca)

BIBLIOGRAPHY

* Journal papers
* Websites

APPENDIX

* Contributing experts
* Conferences attended
* Datamonitor drug assessment scorecard methodology

TABLES

* Table: Summary of the ICD-10 codes used to define asthma, 2012
* Table: Key marketed and pipeline products for asthma, 2012
* Table: Advair (fluticasone/salmeterol; GlaxoSmithKline) - drug profile, 2011
* Table: Overview of pivotal trial data for Advair in asthma, 2012
*

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4343...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.